Frontline oral arsenic trioxide-based induction in newly diagnosed acute promyelocytic leukaemia

Professor Singh, Gill Harinder Harry   (Principal Investigator (PI))

36

2023-03-01

7219547

Frontline oral arsenic trioxide-based induction in newly diagnosed acute promyelocytic leukaemia

Frontline oral arsenic, trioxide-based induction, newly diagnosed, acute promyelocytic leukaemia

Medicine, Dentistry and Health

PRP/029/22FX

Partnership Research Programme (PRP) - 2022

2023

On-going

Introduction:1. Acute promyelocytic leukaemia (APL) is a serious blood cancer that kills a patient within days.2. Arsenic trioxide (ATO) is extremely efficacious for APL. 3. Our team invented and patented the world’s first Good Manufacturing Practice (GMP) grade oral-ATO for treating APL 4. We have extensively tested oral-ATO in APL in Hong Kong, confirming its efficacy and safety.5. Oral-ATO is now manufactured by American Unicorn Laboratories Limited, a subsidiary of Jacobson Pharma Corporation Limited in Hong Kong. Key objectives:1. To provide oral-ATO to patients in the Greater Bay area2. To provide oral-ATO to patients in South East Asia3. To conduct a multi-centre prospective study involving Hong Kong, Shenzhen and Singapore. Key deliverables and outcomes:1. Successful treatment of APL patients in the Greater Bay area and South East Asia2. Provision of oral-ATO as a prescription medication to the Greater Bay Area and South East Asian countries3. The ultimate purpose is global provision of oral-ATO as a prescription medicationSocietal and economic impacts:1. Ensure oral-ATO, originating from Hong Kong, to be available to patients in the Greater Bay area and South East Asia2. Create jobs and research opportunities for scientific research in leukaemia